{"log_id": 6562411906197294610, "direction": 0, "words_result_num": 33, "words_result": [{"probability": {"variance": 0.009842, "average": 0.827359, "min": 0.728151}, "location": {"width": 32, "top": 11, "height": 27, "left": 1105}, "words": "j品"}, {"probability": {"variance": 0, "average": 0.999898, "min": 0.999898}, "location": {"width": 30, "top": 50, "height": 29, "left": 1105}, "words": "准"}, {"probability": {"variance": 0.000224, "average": 0.994471, "min": 0.908747}, "location": {"width": 742, "top": 134, "height": 52, "left": 247}, "words": "在13~17岁年龄组中证实了泊沙康唑的安全性和有效性。尚未确定泊沙康唑在13岁以"}, {"probability": {"variance": 0.00069, "average": 0.990551, "min": 0.896731}, "location": {"width": 279, "top": 196, "height": 36, "left": 212}, "words": "下儿童患者中的安全性和有效性"}, {"probability": {"variance": 1.1e-05, "average": 0.997523, "min": 0.983991}, "location": {"width": 730, "top": 226, "height": 48, "left": 252}, "words": "充分并且良好对照的成人研究以及其他数据为泊沙康唑在这些人群中的使用提供了佐"}, {"probability": {"variance": 0, "average": 0.99938, "min": 0.99938}, "location": {"width": 24, "top": 295, "height": 24, "left": 214}, "words": "证"}, {"probability": {"variance": 5.8e-05, "average": 0.99395, "min": 0.96559}, "location": {"width": 740, "top": 305, "height": 52, "left": 254}, "words": "共有12名13至17岁的患者接受每日600mg(200mg,每日三次)剂量,以预防侵袭"}, {"probability": {"variance": 0.000666, "average": 0.993771, "min": 0.834594}, "location": {"width": 779, "top": 347, "height": 49, "left": 215}, "words": "性真菌感染。这些小于18岁的患者中的安全性与成人相似。根据10名儿童患者中的药代动"}, {"probability": {"variance": 0.006844, "average": 0.977513, "min": 0.498464}, "location": {"width": 711, "top": 387, "height": 48, "left": 218}, "words": "力学数据,这些患者和成人(≥18岁)中的稳态泊沙康唑浓度(Cay)平均值相似"}, {"probability": {"variance": 0.000678, "average": 0.988421, "min": 0.892981}, "location": {"width": 726, "top": 427, "height": 45, "left": 257}, "words": "在涉及另一项适应症的研究中,共有16名8至17岁的患者接受每日800mg(400mg"}, {"probability": {"variance": 0.000531, "average": 0.994496, "min": 0.847658}, "location": {"width": 780, "top": 464, "height": 50, "left": 219}, "words": "每日2次或200mg,每日4次)剂量治疗。根据12名儿童患者的药代动力学数据,这些患"}, {"probability": {"variance": 0.000232, "average": 0.989345, "min": 0.953126}, "location": {"width": 543, "top": 510, "height": 43, "left": 221}, "words": "者和成人(≥18岁)中的稳态泊沙康唑浓度(Cav)平均值相似"}, {"probability": {"variance": 0.000232, "average": 0.990475, "min": 0.943733}, "location": {"width": 732, "top": 543, "height": 48, "left": 261}, "words": "在预防性研究中,10名青少年(13-17岁)和成人(≥18岁)的稳态泊沙康唑浓度(Cav)"}, {"probability": {"variance": 0.000878, "average": 0.990475, "min": 0.847302}, "location": {"width": 778, "top": 582, "height": 50, "left": 224}, "words": "平均值相似。这与另一项研究的药代动力学数据一致,其中12名青少年患者(8-17岁)与"}, {"probability": {"variance": 0.016174, "average": 0.963733, "min": 0.369508}, "location": {"width": 417, "top": 631, "height": 42, "left": 226}, "words": "成人(≥18岁)的稳态泊沙康唑Ca平均值相似"}, {"probability": {"variance": 1e-06, "average": 0.998507, "min": 0.996761}, "location": {"width": 112, "top": 690, "height": 31, "left": 231}, "words": "【老年用药】"}, {"probability": {"variance": 0.000287, "average": 0.993954, "min": 0.895649}, "location": {"width": 738, "top": 706, "height": 48, "left": 268}, "words": "在预防性临床试验中随机接受泊沙康唑治疗的605名患者中,63名(10%)患者的年"}, {"probability": {"variance": 0.014354, "average": 0.963559, "min": 0.351664}, "location": {"width": 776, "top": 745, "height": 51, "left": 231}, "words": "龄≥65岁。此外,在另一项适应症中接受>每日800mg泊沙康唑治疗的48名患者的年龄65"}, {"probability": {"variance": 0.014205, "average": 0.955665, "min": 0.431473}, "location": {"width": 780, "top": 780, "height": 58, "left": 229}, "words": "岁。在老年患者和年轻患者之间,泊沙康唑的安全性不存在总体差异;因此不建议在年"}, {"probability": {"variance": 8e-05, "average": 0.995941, "min": 0.97068}, "location": {"width": 182, "top": 841, "height": 32, "left": 231}, "words": "患者中进行剂量调整"}, {"probability": {"variance": 0.023961, "average": 0.948452, "min": 0.375997}, "location": {"width": 785, "top": 851, "height": 71, "left": 271}, "words": "在年轻和老年(≥65岁)受试者中,泊沙康唑的药代动力学相似。在老年总65岁"}, {"probability": {"variance": 5.3e-05, "average": 0.995067, "min": 0.973653}, "location": {"width": 396, "top": 929, "height": 38, "left": 234}, "words": "患者中,不需要根据年龄对本品进行剂量调整"}, {"probability": {"variance": 1e-05, "average": 0.99807, "min": 0.986151}, "location": {"width": 737, "top": 966, "height": 44, "left": 276}, "words": "在临床试验期间,在老年和年轻受试者中的药代动力学和安全性没有总体差异,但不能"}, {"probability": {"variance": 1e-06, "average": 0.998941, "min": 0.995833}, "location": {"width": 263, "top": 1023, "height": 34, "left": 235}, "words": "排除某些老年人的敏感性更大"}, {"probability": {"variance": 7e-06, "average": 0.99784, "min": 0.991837}, "location": {"width": 147, "top": 1105, "height": 30, "left": 249}, "words": "【药物相互作用】"}, {"probability": {"variance": 0, "average": 0.978054, "min": 0.978054}, "location": {"width": 120, "top": 1059, "height": 76, "left": 913}, "words": "医"}, {"probability": {"variance": 0.000761, "average": 0.987864, "min": 0.846563}, "location": {"width": 720, "top": 1137, "height": 42, "left": 280}, "words": "泊沙康唑主要通过UDP葡糖苷酸化进行代谢,并且是p糖蛋白(P-gp)泵出作用的底物"}, {"probability": {"variance": 2.8e-05, "average": 0.997041, "min": 0.979206}, "location": {"width": 777, "top": 1182, "height": 42, "left": 241}, "words": "因此,这些清除途径的抑制剂或诱导剂可对泊沙康唑的血浆浓度产生影响。泊沙康唑也是"}, {"probability": {"variance": 0.00037, "average": 0.993731, "min": 0.87766}, "location": {"width": 722, "top": 1227, "height": 43, "left": 273}, "words": "3A4的强效抑制剂。因此泊沙康唑可以增加主要通过CYP3A4代谢的药物的血浆浓度"}, {"probability": {"variance": 2.6e-05, "average": 0.995746, "min": 0.980852}, "location": {"width": 304, "top": 1282, "height": 33, "left": 281}, "words": "1、通过CYP3A4代谢的免疫抑制剂"}, {"probability": {"variance": 0.001235, "average": 0.992166, "min": 0.778902}, "location": {"width": 737, "top": 1319, "height": 39, "left": 284}, "words": "西罗莫司:泊沙康唑与西罗莫司联合用药可导致西罗莫司血液浓度约升高9倍,从而会"}, {"probability": {"variance": 3.1e-05, "average": 0.997078, "min": 0.97335}, "location": {"width": 509, "top": 1368, "height": 35, "left": 247}, "words": "导致西罗莫司中毒。因此禁止泊沙康唑与西罗莫司联合使用"}, {"probability": {"variance": 0.009759, "average": 0.974611, "min": 0.380027}, "location": {"width": 725, "top": 1408, "height": 40, "left": 287}, "words": "他克莫司:泊沙康唑可导致他克莫司的Cm和AUC值显著增加。在开始泊沙康唑治疗时"}], "language": 3}